臺北醫學大學新藥開發研究中心

2024

Correction to: The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells (Cell Death & Disease, (2013), 4, 9, (e810), 10.1038/cddis.2013.330)

Chen, M. C., Chen, C. H., Wang, J. C., Tsai, A. C., Liou, J. P., Pan, S. L. & Teng, C. M., 7月 2024, 於: Cell Death and Disease. 15, 7, 490.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

Erratum: Correction: Parallel Screening of Wild-Type and Drug-Resistant Targets for Anti-Resistance Neuraminidase Inhibitors (PloS one (2013) 8 2 DOI: 10.1371/journal.pone.0056704)

Hsu, K. C., Hung, H. C., Horng, J. T., Fang, M. Y., Chang, C. Y., Li, L. T., Chen, I. J., Chen, Y. C., Chou, D. L., Chang, C. W., Hsieh, H. P., Yang, J. M. & Hsu, J. T. A., 2024, 於: PLoS ONE. 19, 11, p. e0314066

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

2023

Author Correction: An ATP-sensitive phosphoketolase regulates carbon fixation in cyanobacteria (Nature Metabolism, (2023), 5, 7, (1111-1126), 10.1038/s42255-023-00831-w)

Lu, K. J., Chang, C. W., Wang, C. H., Chen, F. Y. H., Huang, I. Y., Huang, P. H., Yang, C. H., Wu, H. Y., Wu, W. J., Hsu, K. C., Ho, M. C., Tsai, M. D. & Liao, J. C., 2023, (接受/付印) 於: Nature Metabolism.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

Corrigendum to “Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer” [Biochem. Biophys. Res. Commun. 680 (2023) 161–170, (S0006291X23010616), (10.1016/j.bbrc.2023.09.025)]

Chiang, C. W., Lin, Y. S., Chang, F. L., Lin, T. Y., Tsai, K. C., HuangFu, W. C. & Lee, Y. C., 12月 17 2023, 於: Biochemical and Biophysical Research Communications. 686, 149085.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

Erratum: CuI-mediated synthesis of 1-aryl-5,6,7-trimethoxybenzimidazoles as potent antitubulin agents (RSC Adv. (2023) 13 (13169–13176) DOI: 10.1039/D3RA01927F)

Peng, C. M., Wang, S. W., Hwang, Y. L., Sun, W. C., Chiu, L. P., Liu, Y. T., Lai, Y. W. & Lee, H. Y., 5月 16 2023, 於: RSC Advances. 13, 22, p. 14878 1 p.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

Erratum: N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling (J. Med. Chem. (2015) 58:16 (6549−6558) DOI: 10.1021/acs.jmedchem.5b00659)

Lai, M. J., Lee, H. Y., Chuang, H. Y., Chang, L. H., Tsai, A. C., Chen, M. C., Huang, H. L., Wu, Y. W., Teng, C. M., Pan, S. L., Liu, Y. M., Mehndiratta, S. & Liou, J. P., 5月 11 2023, 於: Journal of Medicinal Chemistry. 66, 9, p. 6436 1 p.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

1 引文斯高帕斯（Scopus）

2022

Correction: Chondroitin sulfate proteoglycan 4 regulates zebrafish body axis organization via Wnt/planar cell polarity pathway (PLoS ONE (2020) 15:4 (e0230943) DOI: 10.1371/journal.pone.0230943)

Lee, Y. H., Kawakami, K., HuangFu, W. C. & Liu, I. H., 6月 2022, 於: PLoS ONE. 17, 6 June, e0270539.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

2021

Diversity in immunogenomics: the value and the challenge

Peng, K., Safonova, Y., Shugay, M., Popejoy, A. B., Rodriguez, O. L., Breden, F., Brodin, P., Burkhardt, A. M., Bustamante, C., Cao-Lormeau, V. M., Corcoran, M. M., Duffy, D., Fuentes-Guajardo, M., Fujita, R., Greiff, V., Jönsson, V. D., Liu, X., Quintana-Murci, L., Rossetti, M. & Xie, J. 及其他15, Yaari, G., Zhang, W., Abedalthagafi, M. S., Adekoya, K. O., Ahmed, R. A., Chang, W. C., Gray, C., Nakamura, Y., Lees, W. D., Khatri, P., Alachkar, H., Scheepers, C., Watson, C. T., Karlsson Hedestam, G. B. & Mangul, S., 6月 2021, 於: Nature Methods. 18, 6, p. 588-591 4 p.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

36 引文斯高帕斯（Scopus）

2020

Correction: Role of integrin-linked kinase in regulating the protein stability of the MUC1-C oncoprotein in pancreatic cancer cells (Oncogenesis, (2017), 6, 7, (e359), 10.1038/oncsis.2017.61)

Huang, H. L., Wu, H. Y., Chu, P. C., Lai, I. L., Huang, P. H., Kulp, S. K., Pan, S. L., Teng, C. M. & Chen, C. S., 2月 1 2020, 於: Oncogenesis. 9, 2, 27.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

Corrigendum to: TW-01, a piperazinedione-derived compound, inhibits Ras-mediated cell proliferation and angioplasty-induced vascular restenosis “Toxicol Appl Pharmacol. 2016;305:194–202” (Toxicology and Applied Pharmacology (2016) 305 (194–202)(S0041008X16301478)(10.1016/j.taap.2016.06.013))

Lin, C. F., Huang, H. L., Peng, C. Y., Lee, Y. C., Wang, H. P., Teng, C. M. & Pan, S. L., 1月 15 2020, 於: Toxicology and Applied Pharmacology. 387, 114858.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

Corrigendum to “Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response” [Eur J Med Chem. 192 2020 112158] (European Journal of Medicinal Chemistry (2020) 192, (S0223523420301252), (10.1016/j.ejmech.2020.112158))

Wu, W. C., Liu, Y. M., Lin, M. H., Liao, Y. H., Lai, M. J., Chuang, H. Y., Hung, T. Y., Chen, C. H. & Liou, J. P., 6月 15 2020, 於: European Journal of Medicinal Chemistry. 196, 112329.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

1 引文斯高帕斯（Scopus）

Corrigendum to“Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo”[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086] (European Journal of Medicinal Chemistry (2020) 190, (S0223523420300532), (10.1016/j.ejmech.2020.112086))

Ojha, R., Nepali, K., Chen, C. H., Chuang, K. H., Wu, T. Y., Lin, T. E., Hsu, K. C., Chao, M. W., Lai, M. J., Lin, M. H., Huang, H. L., Chang, C. D., Pan, S. L., Chen, M. C. & Liou, J. P., 9月 1 2020, 於: European Journal of Medicinal Chemistry. 201, 112404.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

1 引文斯高帕斯（Scopus）

Corrigendum to “N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression”[Eur. J. Med. Chem. 2020 Jan 1;185:111725] (European Journal of Medicinal Chemistry (2020) 185, (S0223523419308773), (10.1016/j.ejmech.2019.111725))

Mehndiratta, S., Lin, M. H., Wu, Y. W., Chen, C. H., Wu, T. Y., Chuang, K. H., Chao, M. W., Chen, Y. Y., Pan, S. L., Chen, M. C. & Liou, J. P., 8月 1 2020, 於: European Journal of Medicinal Chemistry. 199, 112406.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

1 引文斯高帕斯（Scopus）

2019

Correction to: Inhaled gold nanoparticles cause cerebral edema and upregulate endothelial aquaporin 1 expression, involving caveolin 1 dependent repression of extracellular regulated protein kinase activity (Particle and Fibre Toxicology (2019) 16 (37) DOI: 10.1186/s12989-019-0324-2)

Chen, C. Y., Liao, P. L., Tsai, C. H., Chan, Y. J., Cheng, Y. W., Hwang, L. L., Lin, K. H., Yen, T. L. & Li, C. H., 11月 18 2019, 於: Particle and Fibre Toxicology. 16, 1, 43.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

1 引文斯高帕斯（Scopus）

Correction to: Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway (Journal of Biomedical Science (2019) 26 (96) DOI: 10.1186/s12929-019-0588-8)

Wakabayashi, G., Lee, Y. C., Luh, F., Kuo, C. N., Chang, W. C. & Yen, Y., 12月 23 2019, 於: Journal of Biomedical Science. 26, 1, 98.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

1 引文斯高帕斯（Scopus）

2018

Erratum: Author Correction: Poly-protein G-expressing bacteria enhance the sensitivity of immunoassays (Scientific reports (2017) 7 1 (989))

Hao, W. R., Chen, M., Chen, Y. J., Su, Y. C., Cheng, C. M., Hsueh, H. Y., Kao, A. P., Hsieh, Y. C., Chang, J., Tseng, M. Y. & Chuang, K. H., 3月 6 2018, 於: Scientific Reports. 8, 1, p. 4256 1 p., 4256.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

開啟存取

2013

Erratum: MPT0B098, a novel microtubule inhibitor that destabilizes the hypoxia-inducible factor-1α mrna through decreasing nuclear-cytoplasmic translocation of RNA-binding protein HuR (Molecular Cancer Therapeutics (2013) 12 (1202-12))

Cheng, Y. C., Liou, J. P., Kuo, C. C., Lai, W. Y., Shih, K. H., Chang, C. Y., Pan, W. Y., Tseng, J. T. & Chang, J. Y., 9月 2013, 於: Molecular Cancer Therapeutics. 12, 9, p. 1919 1 p.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

2011

(Journal of Food and Drug Analysis 18, 6, (380))

Cheng, Y. W. & Lou, H. Y., 6月 2011, 於: Journal of Food and Drug Analysis. 19, 2, p. 243 1 p.

研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審

臺北醫學大學新藥開發研究中心

研究成果

搜尋結果